Drug Safety Update – MHRA – Yellow Fever vaccine

Drug Safety Update – MHRA – Yellow Fever vaccine

Yellow fever vaccine – following two fatalities – the vaccine must not be given to patients that present with a history of thymus dysfunction, or is immunosuppressed. The MHRA advise clinicians use extreme caution in administering the vaccine in people over 60 due to an increased risk of an Adverse Reaction – ADR

The use of Valoprate medicines pre and during pregnancy. Valoprate is a medicine used in the treatment of epilepsy and bipolar condition. It has been known that this drug causes significant birth defects in children born to patients using valproate. The MHRA has provided a revised Annual Risk Acknowledgement for clinicians to use on all females of childbearing age. They issued a reminder that there is no safe dose of valproate that can be used in pregnancy.